University of Oklahoma-College of Medicine: Stem Cell Therapy Furthers Research for Infants With Hypoplastic Left Heart Syndrome
July 22, 2019
July 22, 2019
ROCHESTER, Minnesota, July 22 [TNSmedicalresearch] -- The University of Oklahoma's College of Medicine issued the following news:
A phase I clinical trial is the first research monitored by the Food and Drug Administration that demonstrates the potential of regenerative therapy for hypoplastic left heart syndrome (HLHS) through collecting, processing and injecting an infant's own stem cells directly into the heart at the time of surgery. A paper detailing the clinical tria . . .
A phase I clinical trial is the first research monitored by the Food and Drug Administration that demonstrates the potential of regenerative therapy for hypoplastic left heart syndrome (HLHS) through collecting, processing and injecting an infant's own stem cells directly into the heart at the time of surgery. A paper detailing the clinical tria . . .